j, k, When AEF0117 was administered in the first study period (AEF0117 first, n = 6 for the 0.06-mg cohort; n = 7 and 8 for the 1-mg cohort for placebo and AEF0117, respectively), detectable levels of AEF0117 were observed in the second dosing period when participants received placebo >=14 d after AEF0117 administration. This was not the case when AEF0117 was administered in the second dosing period (placebo first, n = 8 and 7 per dose for the 0.06-mg and 1-mg cohorts, respectively). Data are represented as mean +/- s.e.m. over the different days of testing for each timepoint (a – h, j, k) or as overall rating over the 5 d of testing and the five timepoints (i). AEF, AEF0117; D, days; SA, self-administration; PD, pre-dose.
